EXPRESSION OF β-ENDORPHIN IN HYPERTROPHIC SCAR AND ITS RELATIONSHIP WITH PRURITUS_Chinese Journal of Reparative and Reconstructive Surgery

Authors：

ZHU Jiangting ^1,2 , CHENG Biao ² , LIU Hongwei ³ , TANG Jianbing ² , XIANG Xiaofei ² , PENG Yan ²

1Graduate School of Southern Medical University, Guangzhou Guangdong, 510515, P.R.China;;
2Department of Plastic Surgery, the Key Laboratory of Trauma Treatment &;
Tissue Repair of Tropical Area of Chinese PLA, Guangzhou General Hospital of Guangzhou Military Command;;
3Department of Plastic Surgery, the Key Laboratory of Tissue Regeneration of the Ministry of Education, the First Affiliated Hospital of Jinan University.;

Corresponding author：

Keywords：

Hypertrophic scar β-endorphin; Paresthesia; Opioid peptide

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To identify the effect of β-endorphin in the development of paresthesia in hypertrophic scar by detecting the expression and content of β-endorphin in human normal skin and hypertrophic scar. Methods Hypertrophic scar samples were collected from 42 patients with hypertrophic scar for 1-20 years (mean, 4.5 years), including 15 males and
27 females with an average age of 32.6 years (range, 16-50 years). According to the kind of paresthesia, they were divided into 3 gourps: non-pain-pruritus group (n=20), pruritus group (n=14), and pain-pruritus group (n=8). Normal skin samples (normal skin group) were harvested from 5 patients undergoing skin grafting surgery, including 3 males and 2 females with an average age of 24.6 years (range, 15-37 years). The immunofluorescence method was used to observe the expression of β-endorphin and ELISA method to detect the concentrations of β-endorphin in the tissues. Results The β-endorphin expressed in all samples, and it expressed around peri pheral nerve fibers in the dermis, fibroblasts, and monocytoid cells princi pally; and it expressed significantly ber in pruritus group and pain-pruritus group than in non-pain-pruritus group and normal skin group. The β-endorphin content was (617.401 ± 97.518) pg/mL in non-pain-pruritus group, (739.543 ± 94.149) pg/mL in pruritus group, (623.294 ± 149.613) pg/mL in pain-pruritus group, and (319.734 ± 85.301) pg/mL in normal skin group; it was significantly higher in non-pain-pruritus group, pruritus group, and pain-pruritus group than in normal skin group (P lt; 0.05); it was significantly higher in pruritus group than in non-pain-pruritus group and pain-pruritus group (P lt; 0.05); and there was no significant difference between non-pain-pruritus group and pain-pruritus group (P gt; 0.05). Conclusion The expression of β-endorphin is high in hypertrophic scar, it may paly an important role in process of pruritus in these patients.

Citation： ZHU Jiangting,CHENG Biao,LIU Hongwei,TANG Jianbing,XIANG Xiaofei,PENG Yan. EXPRESSION OF β-ENDORPHIN IN HYPERTROPHIC SCAR AND ITS RELATIONSHIP WITH PRURITUS. Chinese Journal of Reparative and Reconstructive Surgery, 2012, 26(6): 731-734. doi: Copy

1.	Profyris C, Tziotzios C, Do Vale I, et al. Cutaneous scarring: Pathophysiology, molecular mechanisms, and scar reduction therapeutics Part I. The molecular basis of scar formation. J Am Acad Dermatol, 2012, 66(1): 1-10.
2.	Akaishi S, Ogawa R, Hyakusoku H. Keloid and hypertrophic scar: neurogenic inflammation hypotheses. Med Hypotheses, 2008, 71(1): 32-38.
3.	Pitzer GB, Patel KG. Proper care of early wounds to optimize healing and prevent complications. Facial Plast Surg Clin North Am, 2011, 19(3): 491-504.
4.	Gauglitz GG, Korting HC, Pavicic T, et al. Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies. Mol Med, 2011, 17(1-2): 113-125.
5.	程飚, 刘宏伟, 李勤, 等. β-内啡肽与μ-阿片受体在正常皮肤与增生性瘢痕组织中的分布特征与生物学意义. 中华整形外科杂志, 2008, 24(5): 343-346.
6.	叶巧园, 樊翌明. P物质、蛋白酶、阿片样肽3种非组胺依赖性瘙痒介质的研究进展. 广东医学院学报, 2008, 26(5): 553-556.
7.	Bigliardi PL, Tobin DJ, Gaveriaux-Ruff C, et al. Opioids and the skin—where do we stand? Exp Dermatol, 2009, 18(5): 424-430.
8.	刘莉萍, 范卫新. β-内啡肽在皮肤中的作用. 临床皮肤科杂志, 2006, 35(3): 192-193.
9.	Bigliardi-Qi M, Sumanovski LT, Buchner S, et al. Mu-opiate receptor and Beta-endorphin expression in nerve endings and keratinocytes in human skin. Dermatology, 2004, 209(3): 183-189.
10.	Cheng B, Liu HW, Fu XB, et al. Update on pruritic mechanisms of hypertrophic scars in postburn patients: the potential role of opioids and their receptors. J Burn Care Res, 2011, 32(4): e118-125.
11.	Van Loey NE, Bremer M, Faber AW, et al. Itching following burns: epidemiology and predictors. Br J Dermatol, 2008, 158(1): 95-100.
12.	Nelson RD. Postburn itch//Yosipovitch G, Greaves MW, Fleischer AB, et al. Itch: basic mechanism and therapy. New York: Marcel Dekker, 2004: 247-254.
13.	Forbes-Duchart L, Cooper J, Nedelec B, et al. Burn therapists’ opinion on the application and essential characteristics of a burn scar outcome measure. J Burn Care Res, 2009, 30(5): 792-800.
14.	Bigliardi-Qi M, Lipp B, Sumanovski LT, et al. Changes of epidermal mu-opiate receptor expression and nerve endings in chronic atopic dermatitis. Dermatology, 2005, 210(2): 91-99.
15.	Taneda K, Tominaga M, Negi O, et al. Evaluation of epidermal nerve density and opioid receptor levels in psoriatic itch. Br J Dermatol, 2011, 165(2): 277-284.
16.	Cheng B, Liu HW, Fu XB, et al. Coexistence and upregulation of three types of opioid receptors, mu, delta and kappa, in human hypertrophic scars. Br J Dermatol, 2008, 158(4): 713-720.
17.	Ikoma A, Steinhoff M, Ständer S, et al. The neurobiology of itch. Nat Rev Neurosci, 2006, 7(7): 535-547.
18.	Goutos I. Burns pruritus—a study of current practices in the UK. Burns, 2010, 36(1): 42-48.
19.	Baker RA, Zeller RA, Klein RL, et al. Burn wound itch control using H1 and H2 antagonists. J Burn Care Rehabil, 2008, 22(4): 263-268.

1. Profyris C, Tziotzios C, Do Vale I, et al. Cutaneous scarring: Pathophysiology, molecular mechanisms, and scar reduction therapeutics Part I. The molecular basis of scar formation. J Am Acad Dermatol, 2012, 66(1): 1-10.
2. Akaishi S, Ogawa R, Hyakusoku H. Keloid and hypertrophic scar: neurogenic inflammation hypotheses. Med Hypotheses, 2008, 71(1): 32-38.
3. Pitzer GB, Patel KG. Proper care of early wounds to optimize healing and prevent complications. Facial Plast Surg Clin North Am, 2011, 19(3): 491-504.
4. Gauglitz GG, Korting HC, Pavicic T, et al. Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies. Mol Med, 2011, 17(1-2): 113-125.
5. 程飚, 刘宏伟, 李勤, 等. β-内啡肽与μ-阿片受体在正常皮肤与增生性瘢痕组织中的分布特征与生物学意义. 中华整形外科杂志, 2008, 24(5): 343-346.
6. 叶巧园, 樊翌明. P物质、蛋白酶、阿片样肽3种非组胺依赖性瘙痒介质的研究进展. 广东医学院学报, 2008, 26(5): 553-556.
7. Bigliardi PL, Tobin DJ, Gaveriaux-Ruff C, et al. Opioids and the skin—where do we stand? Exp Dermatol, 2009, 18(5): 424-430.
8. 刘莉萍, 范卫新. β-内啡肽在皮肤中的作用. 临床皮肤科杂志, 2006, 35(3): 192-193.
9. Bigliardi-Qi M, Sumanovski LT, Buchner S, et al. Mu-opiate receptor and Beta-endorphin expression in nerve endings and keratinocytes in human skin. Dermatology, 2004, 209(3): 183-189.
10. Cheng B, Liu HW, Fu XB, et al. Update on pruritic mechanisms of hypertrophic scars in postburn patients: the potential role of opioids and their receptors. J Burn Care Res, 2011, 32(4): e118-125.
11. Van Loey NE, Bremer M, Faber AW, et al. Itching following burns: epidemiology and predictors. Br J Dermatol, 2008, 158(1): 95-100.
12. Nelson RD. Postburn itch//Yosipovitch G, Greaves MW, Fleischer AB, et al. Itch: basic mechanism and therapy. New York: Marcel Dekker, 2004: 247-254.
13. Forbes-Duchart L, Cooper J, Nedelec B, et al. Burn therapists’ opinion on the application and essential characteristics of a burn scar outcome measure. J Burn Care Res, 2009, 30(5): 792-800.
14. Bigliardi-Qi M, Lipp B, Sumanovski LT, et al. Changes of epidermal mu-opiate receptor expression and nerve endings in chronic atopic dermatitis. Dermatology, 2005, 210(2): 91-99.
15. Taneda K, Tominaga M, Negi O, et al. Evaluation of epidermal nerve density and opioid receptor levels in psoriatic itch. Br J Dermatol, 2011, 165(2): 277-284.
16. Cheng B, Liu HW, Fu XB, et al. Coexistence and upregulation of three types of opioid receptors, mu, delta and kappa, in human hypertrophic scars. Br J Dermatol, 2008, 158(4): 713-720.
17. Ikoma A, Steinhoff M, Ständer S, et al. The neurobiology of itch. Nat Rev Neurosci, 2006, 7(7): 535-547.
18. Goutos I. Burns pruritus—a study of current practices in the UK. Burns, 2010, 36(1): 42-48.
19. Baker RA, Zeller RA, Klein RL, et al. Burn wound itch control using H1 and H2 antagonists. J Burn Care Rehabil, 2008, 22(4): 263-268.

Chinese Journal of Reparative and Reconstructive Surgery

EXPRESSION OF β-ENDORPHIN IN HYPERTROPHIC SCAR AND ITS RELATIONSHIP WITH PRURITUS

Abstract Full text Figures/Tables Video References Cited by

Format

Content